Regorafenib belongs to this second-generation of oral multikinase inhibitors that blocks the activity of several kinases, including those involved in the regulation of tumor angiogenesis (VEGFR1-3 and TIE2), oncogenesis (KIT, RET, RAF1, BRAF and BRAFV600E) and the tumor microenvironment (PDGFRβ and FGFR). The gene discussed is FLT1; the disease is neoplasm.